Schrödinger, Inc. (NASDAQ:SDGR) Receives $32.90 Average Target Price from Analysts

Shares of Schrödinger, Inc. (NASDAQ:SDGR) have been assigned an average rating of “Moderate Buy” from the eleven research firms that are presently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $32.90.

A number of analysts have commented on SDGR shares. BMO Capital Markets raised their price objective on Schrödinger from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Morgan Stanley reduced their price objective on Schrödinger from $43.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 21st.

Insider Buying and Selling

In related news, insider Margaret Dugan sold 1,531 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $17.78, for a total transaction of $27,221.18. Following the completion of the transaction, the insider now owns 13,469 shares in the company, valued at $239,478.82. This trade represents a 10.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 8.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Schrödinger

Hedge funds and other institutional investors have recently bought and sold shares of the business. Nisa Investment Advisors LLC increased its holdings in Schrödinger by 145.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,413 shares of the company’s stock valued at $27,000 after purchasing an additional 837 shares in the last quarter. GAMMA Investing LLC increased its holdings in Schrödinger by 49.5% during the 2nd quarter. GAMMA Investing LLC now owns 2,124 shares of the company’s stock valued at $41,000 after purchasing an additional 703 shares in the last quarter. KBC Group NV increased its holdings in Schrödinger by 45.4% during the 3rd quarter. KBC Group NV now owns 2,508 shares of the company’s stock valued at $47,000 after purchasing an additional 783 shares in the last quarter. Quarry LP increased its holdings in Schrödinger by 1,150.0% during the 3rd quarter. Quarry LP now owns 2,825 shares of the company’s stock valued at $52,000 after purchasing an additional 2,599 shares in the last quarter. Finally, nVerses Capital LLC acquired a new stake in Schrödinger during the 2nd quarter valued at $66,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Schrödinger Stock Down 3.8 %

SDGR opened at $21.46 on Friday. The firm has a market capitalization of $1.56 billion, a P/E ratio of -9.17 and a beta of 1.50. The stock’s 50 day moving average price is $18.68 and its two-hundred day moving average price is $20.17. Schrödinger has a 12-month low of $16.67 and a 12-month high of $38.00.

Schrödinger (NASDAQ:SDGR) last released its earnings results on Tuesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.12). The business had revenue of $35.30 million during the quarter, compared to analyst estimates of $41.25 million. Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. The business’s quarterly revenue was down 17.1% compared to the same quarter last year. During the same period last year, the business earned ($0.86) EPS. As a group, analysts anticipate that Schrödinger will post -2.29 earnings per share for the current year.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.